Opinion|Videos|July 23, 2024
Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- After frontline therapy in limited-stage small cell lung cancer (LS-SCLC), how do you determine the appropriate second-line and subsequent therapy?
- What patient-specific factors do you consider?
- Other than clinical trial enrollment, what would you consider for second-line treatment?
- Please briefly describe the SWOG umbrella protocol for ES-SCLC
- Can we personalize treatment by identifying molecular subtypes that may be more responsive to certain therapies than others?
- Please provide your insights on the potential for improved survival benefits with chemoimmunotherapy and consolidative thoracic radiotherapy in patients with ES-SCLC.
- What additional research should be conducted to further validate the use of CIT and cTRT in this patient population?
- Please briefly comment on key updates in SCLC recently presented at ASCO 2024 and discuss how these findings may impact the overall treatment landscape.
Advertisement
Related to this article
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
4
Dr Graham on Data for JNJ-87189401 Plus Pasritamig in mCRPC
5